Plymouth Meeting, PA – Harmony Biosciences has announced the appointment of Glenn Reicin as Chief Financial Officer. About Harmony Biosciences: Harmony Biosciences Holdings, Inc. is a pharmaceutical company specializing in the development and commercialization of innovative therapies for rare neurological diseases. The company is prominently known for its lead product, WAKIX (pitolisant), which is FDA-approved for treating excessive daytime sleepiness in adult patients with narcolepsy and also for cataplexy in those patients. Headquartered in Plymouth Meeting, Pennsylvania, Harmony focuses on addressing unmet medical needs in the central nervous system space through targeted research and strategic partnerships. On April 14, 2026, the company announced the appointment of Glenn Reicin as its new Chief Financial Officer, highlighting its commitment to strengthening executive leadership to support ongoing growth and operations. With a robust pipeline and a strong market presence in rare disease treatments, Harmony continues to advance therapies that improve patient outcomes in underserved therapeutic areas.

For more information on Harmony Biosciences please visit: https://www.harmonybiosciences.com/

Harmony Biosciences
630 W Germantown Pike
Plymouth Meeting, PA 19462
Phone: 484-539-9800
LinkedIn Page: https://www.linkedin.com/company/harmonybiosciences/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved